175 related articles for article (PubMed ID: 24927266)
21. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
22. An analysis of the safety profile of proteasome inhibitors for treating various cancers.
Wang H; Guan F; Chen D; Dou QP; Yang H
Expert Opin Drug Saf; 2014 Aug; 13(8):1043-54. PubMed ID: 25005844
[TBL] [Abstract][Full Text] [Related]
23. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
24. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
25. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak AJ
Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
[TBL] [Abstract][Full Text] [Related]
26. [Not Available].
Hitz F
Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
[No Abstract] [Full Text] [Related]
27. Clinical translation in multiple myeloma: from bench to bedside.
Laubach J; Hideshima T; Richardson P; Anderson K
Semin Oncol; 2013 Oct; 40(5):549-53. PubMed ID: 24135399
[TBL] [Abstract][Full Text] [Related]
28. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
29. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
30. [Development and clinical application of novel proteasome inhibitors].
Iida S
Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
[No Abstract] [Full Text] [Related]
31. Sequential or combination therapy for multiple myeloma.
Nooka A; Lonial S
Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
[TBL] [Abstract][Full Text] [Related]
32. Real-world renal function among patients with multiple myeloma in the United States.
Mikhael J; Singh E; Rice MS
Blood Cancer J; 2021 May; 11(5):99. PubMed ID: 34021119
[No Abstract] [Full Text] [Related]
33. [Proteasome inhibitors].
Fuchida S; Shimazaki C
Nihon Rinsho; 2015 Feb; 73 Suppl 2():267-71. PubMed ID: 25831765
[No Abstract] [Full Text] [Related]
34. Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma.
Malissen N; Bourrain JL; Chiriac A; Montet A; Vincent L; Dereure O; Du-Thanh A
Acta Derm Venereol; 2016 Nov; 96(7):995-996. PubMed ID: 27001285
[No Abstract] [Full Text] [Related]
35. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941
[No Abstract] [Full Text] [Related]
36. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Broyl A; Jongen JL; Sonneveld P
Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibitors: introduction.
Heuck CJ; Shaughnessy JD
Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
[No Abstract] [Full Text] [Related]
38. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.
Wartman LD; Fiala MA; Fletcher T; Hawkins ER; Cashen A; DiPersio JF; Jacoby MA; Stockerl-Goldstein KE; Pusic I; Uy GL; Westervelt P; Vij R
Leuk Lymphoma; 2016; 57(3):728-30. PubMed ID: 26674111
[No Abstract] [Full Text] [Related]
39. Carfilzomib (Kyprolis°) in multiple myeloma.
Prescrire Int; 2017 May; 26(182):120. PubMed ID: 30730668
[No Abstract] [Full Text] [Related]
40. Emerging therapies for multiple myeloma: Application in older adults.
Wildes TM
J Geriatr Oncol; 2017 Nov; 8(6):413-416. PubMed ID: 28756084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
